Perjeta and Kadcyla HER2 Positive Breast Cancer Market to 2020 in a New Report Available at RnRMarketResearch.com

News provided by

RnR Market Research

Oct 22, 2014, 09:30 ET

Dallas, Texas (PRWEB) October 22, 2014 -- "Perjeta (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023"

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Perjeta (pertuzumab) is the second biologic to launch in Roche/Genentech’s HER2-targeted therapy portfolio, and was approved by the FDA in 2012, and by the EMA and the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2013. Like Herceptin, Perjeta is a monoclonal antibody (mAb) that targets HER2; however, Perjeta’s mechanism of action is slightly different: whereas Herceptin blocks the binding of ligands to HER2, Perjeta binds to the extracellular dimerization domain of HER2, inhibiting ligand-dependent dimerization of the HER receptors.

Complete report on Perjeta (HER2-Positive Breast Cancer) available @ http://www.rnrmarketresearch.com/perjeta-her2-positive-breast-cancer-forecast-and-market-analysis-to-2023-market-report.html .

Scope
• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Perjeta including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Perjeta for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Order a Purchase copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=232640 .

Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Kadcyla (ado-trastuzumab) is Roche’s third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).

Complete report on Kadcyla (HER2-Positive Breast Cancer) available at http://www.rnrmarketresearch.com/kadcyla-her2-positive-breast-cancer-forecast-and-market-analysis-to-2023-market-report.html .

Scope
• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Kadcyla including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Kadcyla for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Order a Purchase copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=232641 .

Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Kadcyla performance
• Obtain sales forecast for Kadcyla from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Browse more reports on Cancer Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

List of Tables
Table 1: AJCC Stage Definitions for Breast Cancer 16
Table 2: Prognosis for Breast Cancer in the US 17
Table 3: Treatment Guidelines for HER2-Positive Breast Cancer 26
Table 4: Product Profile - Perjeta 31
Table 5: Perjeta SWOT Analysis, 2013 33
Table 6: Global Sales Forecast ($m) for Perjeta, 2013-2023 33
Table 7: HER2-Positive Breast Cancer Incidence, 2013-2023 45
Table 8: Average Body Weight and Surface Area Across the 8MM 46
Table 9: Average Annual Cost of Therapy ($) - Perjeta, First Line 47
Table 10: Physicians Surveyed by Country 50

List of Figures
Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 14
Figure 2: Active Late-Stage Clinical Trials for Perjeta 30

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]